5:27 PM
 | 
Jul 10, 2019
 |  BC Extra  |  Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab

I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for $135 million in development and regulatory milestones, plus tiered double-digit royalties. MacroGenics plans to begin a Phase II trial this year of the Fc-optimized mAb against B7-H3 in combination with PD-1 inhibitor MGA012 (also known as INCMGA0012) to treat first-line head and neck cancer; I-Mab will lead regional studies of enoblituzumab.

Mirati, Novartis to pair KRAS and SHP-2 inhibitors
Mirati Therapeutics Inc. (NASDAQ:MRTX) and Novartis AG (NYSE:NVS; SIX:NOVN) are going after two hot cancer targets in a collaboration to evaluate the combination of Mirati’s MRTX849, a KRAS G12C inhibitor that is in Phase I/II testing, with Novartis’ SHP-2 inhibitor, TNO155, in patients...

Read the full 670 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >